FDA Grants Fast Track Status to Alzheon’s Alzheimer’s Therapy Candidate ALZ-801

FDA Grants Fast Track Status to Alzheon’s Alzheimer’s Therapy Candidate ALZ-801
The U.S. Food and Drug Administration has granted Fast Track status to Alzheon’s Alzheimer’s therapy candidate ALZ-801, which studies have shown prevents the clustering of harmful proteins associated with the disease. “We look forward to working closely with the FDA as we seek to make progress in developing a disease-modifying treatment for Alzheimer’s disease to address

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *